Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 6/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 3/20 | 0.33 |
| ▸ | CHUK | O15111 | 3/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21569598 | 0.87 | PRKCI (0.39) | PRKCIGRM5CA12CYP2D6SLC6A2 | |
| SCHEMBL12948358 | 0.81 | CHEK1 (0.42) | PRKCICA12HSD17B1 | |
| SCHEMBL15782870 | 0.75 | PRKCI (0.37) | PRKCICA12HSD17B1GABRA1GABRB2 | |
| SCHEMBL23735763 | 0.71 | USP2 (0.41) | GRM5DAOIKBKBCHUKBCHE | |
| SCHEMBL15782860 | 0.71 | CA12 (0.44) | PRKCICA12 | |
| SCHEMBL15782879 | 0.71 | SLC2A1 (0.36) | PRKCI | |
| SCHEMBL19841038 | 0.70 | CHEK1 (0.43) | PRKCICA12 | |
| SCHEMBL15782873 | 0.69 | MEN1 (0.50) | PRKCIDAOCA12GABRA1GABRB2 | |
| SCHEMBL15782861 | 0.69 | KCNA3 (0.42) | PRKCICA12 | |
| SCHEMBL22042243 | 0.68 | PRKCI (0.36) | PRKCICA12HSD17B1GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884830-B2 | Synthesis of tetracyclines and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-02-06 | — | — | US | disclosed |
| EP-3138831-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | President and Fellows of Harvard College (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20160340325-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-24 | — | — | US | disclosed |
| EP-1753713-B1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | HARVARD COLLEGE (US) | 2016-07-27 | — | — | EP | disclosed |
| US-9365493-B2 | Synthesis of tetracyclines and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340325-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | TET1, TET3, MYC | PRKCI 2091/4885GRM5 4544/4885DAO 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.